BioStock: Arcede Pharma approaches clinical trial after toxicological results
Lund-based Arcede Pharma has now completed the last major preclinical milestone with RCD405. The results from the final part of the toxicology program showed that the drug candidate was well tolerated. This leaves the door open to initiating clinical studies.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se